Kims-Sunshine Hospital, Hyderabad – India
About Dr. Madala Ravikrishna
Dr. Madala Ravikrishna is a highly accomplished and leading medical and haemato-oncologist in India, renowned for his commitment to patient care and academic excellence. With a robust background from prestigious institutions like Tata Memorial Hospital, Mumbai, he is dedicated to working with utmost sincerity and discipline, tackling challenging cases to advance his knowledge and expertise. Dr. Ravikrishna’s passion lies in providing exceptional patient care, continuously enhancing his skills through diverse clinical scenarios, and contributing meaningfully to the field of oncology. He is recognised as a top oncologist in India for his extensive medical background and dedication to delivering the highest standards of treatment.
Qualifications & Credentials
Medical Degrees
- MBBS
- MD (Radiation Oncology)
- DM (Medical Oncology), Tata Memorial Hospital, Mumbai
Areas of Expertise
Major Cancer Types Treated
- Lung Cancer
- Liver Cancer
- Prostate Cancer
- Pancreatic Cancer
- Gallbladder Cancer
- Blood cancers
- Thoracic cancers
- Head and neck cancers
- Ewing Sarcoma
- Carcinoma Cervix
- Medical Oncology
- Haemato-oncology
- Chemotherapy administration and management
- Targeted therapy
- Immunotherapy
- Management of complex cancer cases
Professional Experience
Current & Past Hospital Affiliations
Current Affiliations: Consultant Medical & Haemato-oncologist, Kims-Sunshine Hospital, Hyderabad
Past Affiliations:
- Consultant, Assistant Professor, Tata Memorial Centre, Mumbai
- Senior Resident, Department of Radiation Oncology, SVIMS, Tirupati
- Intern, Kurnool Medical College
- Former, Assistant Professor, Tata Memorial Centre, Mumbai
- Active participant in numerous presentations and publications at national and international forums.
- Contributed significantly to research on checkpoint inhibitor accessibility in Indian cancer patients.
- Involved in studies concerning vascular endothelial growth factor as a prognosticator in Ewing Sarcoma.
- Authored papers on neurological deterioration in lung cancer patients and impact of prognostic factors in carcinoma cervix.
- Presented at major international conferences like ASCO annual meeting, contributing to global oncology knowledge.
Awards & Recognitions
- Oral presentation at ASCO Annual Meeting 2022 in Chicago: "Checkpoint inhibitor accessibility in 15,000+ Indian patients."
- Oral presentation at ASCO Annual Meeting 2023 in Chicago: "Second line palliative chemo (OMCT vs physician choice) in recurrent metastatic head and neck malignancies."
- Oral presentation at INTERNATIONAL CANCER CONGRESS-2016, Nagpur: "Dosimetric comparison of deep inspiration breath-hold with active breathing coordinator versus free-breathing in carcinoma left breast patients receiving adjuvant radiotherapy."
- Poster presentation at AROICON 2015, Lucknow: "Malignant acrospiroma of chest wall."
Research & Publications
Published Papers in Medical Journals
- "Retrospective analysis: checkpoint inhibitor accessibility for thoracic and head and neck cancers and factors influencing it in a tertiary centre in India." Patil V, Abraham G, Ravikrishna M, Bhattacharjee A, Noronha V, Parekh D, Menon N, Bajpai J, Prabhash K.
- "Vascular endothelial growth factor as a potential prognosticator in Ewing Sarcoma: a tertiary care cancer centre experience from India." Bajpai J, Panda G, Ravikrishna M, Chandrasekharan A, Rekhi B, Bhargava P, Srinivas S, Laskar S, Mokal S, Khanna N, Patil V.
- "Neurological deterioration in a patient with lung cancer and brain metastasis." Madala RK, Krishnatry R, Noronha V, Patil V, Joshi A, Menon N, Muthuluri H, Prabhash K. Cancer
- "Results of phase III randomised trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation." Patil VM, Noronha V, Menon N, Singh A, Ghosh-Laskar S, Budrukkar A, Bhattacharjee A, Swain M, Mathrudev V, Nawale K, Balaji A. Journal of Clinical Oncology (2023).
- "Impact of Various Prognostic Factors on Overall Survival, Disease-Free Survival and Patterns of Failure in Carcinoma Cervix: A Tertiary Care Centre Experience from South India." Prathipati A, Jilla S, Subramanian BV, Madala RK. Indian Journal of Gynecologic Oncology (2018).
- "COVID-19 vaccine uptake and vaccine hesitancy in Indian patients with cancer: A questionnaire-based survey." Noronha V, Abraham G, Bondili SK, Rajpurohit A, Menon RP, Gattani S, Trikha M, Tudu R, Kota KK, Singh AK, Elamarthi P, Panda GS, Rai RK, Krishna MR, Chinthala SK, Shah MJ, Shah D, Tiwari A, Vora DN, Tongaonkar AH, John G, Patil A, Menon NS, Patil VM, Joshi A, Banavali S, Badwe RA, Prabhash K. Cancer Res Stat Treat (2021).
- "Clinical characteristics, laboratory parameters and outcomes of COVID-19 in cancer and non-cancer patients from a tertiary Cancer Centre in India." Mirgh SP, GokarnA, Rajendra A, More A, Kamtalwar S, Katti KS, Singh A, Goli VB, Ravind R, Madala R, Kakoti S, Maitre P, Punatar S, Chichra A, Patil A, Trivedi B, Joshi A, Patkar N, Tembhare P, Khanka T, Rajpal S, Chatterjee G, Kannan S, Subramanian PG, Murthy V, Shetty N, Chavan P, Bhat V, Nair S, Khattry N, Gupta S. Cancer Med (2021).
- "Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial." Patil VM, Menon N, Chatterjee A, Tonse R, Choudhari A, Mahajan A, Puranik AD, Epari S, Jadhav M, Pathak S, Peelay Z. EClinicalMedicine (2022).
Patient Success Stories & Testimonials
Notable Cases Handled
- Instrumental in analysing real-world data on checkpoint inhibitor accessibility for a large cohort of Indian cancer patients, influencing treatment strategies.
- Contributed to understanding neurological complications in lung cancer and brain metastasis, guiding better patient management.
- Played a key role in studies evaluating prognostic factors and outcomes in carcinoma cervix, impacting treatment protocols.
Treatment Approach & Philosophy
Patient-Centred Care
Dr. Madala Ravikrishna is committed to a patient-centred approach, ensuring that each individual receives personalised care tailored to their specific diagnosis and needs. His philosophy emphasises clear communication, empathy, and involving patients in their treatment decisions. He strives to provide comprehensive care with full sincerity and discipline, focusing on both the efficacy of treatment and the patient's quality of life.Technology & Innovation
Dr. Ravikrishna stays abreast of the latest advancements in oncology, integrating modern diagnostic and therapeutic techniques into his practice. His involvement in publishing and presenting cutting-edge research indicates a strong inclination towards leveraging technology and innovation to deliver the most effective and contemporary cancer treatments available.
Treatment Costs
| Treatment Type | Cost in INR (approx.) | Cost in USD (approx.) |
| Lung Cancer Treatment | ₹5,00,000 - ₹15,00,000 | $6,000 - $18,000 |
| Head and Neck Cancer Treatment | ₹4,00,000 - ₹12,00,000 | $5,000 - $15,000 |
| Ewing Sarcoma Treatment | ₹6,00,000 - ₹20,00,000 | $7,000 - $24,000 |
| Chemotherapy cycles (per cycle) | ₹50,000 - ₹2,00,000 | $600 - $2,500 |
| Immunotherapy (per cycle) | ₹1,50,000 - ₹4,00,000 | $1,800 - $5,000 |
International Patient Assistance
Language Support
The Cancer Rounds team typically offers support for international patients, including language services to ensure clear communication throughout the treatment journey.Visa & Travel Assistance
The Cancer Rounds team assists with visa processes, travel arrangements, airport transfers, and accommodation, making the process seamless for international patients.Pre-treatment Virtual Consultations
Telemedicine capabilities are available for initial discussions, review of medical records, and second opinions before international patients travel, facilitating early engagement with Dr. Madala Ravikrishna and the Cancer Rounds team.
Frequently Asked Questions
Dr. Madala Ravikrishna is a leading medical and haemato-oncologist in India, specialising in the medical management of various cancers and blood disorders.
Dr. Madala Ravikrishna treats a broad range of cancers, including thoracic cancers, head and neck cancers, Ewing Sarcoma, lung cancer with brain metastasis, and carcinoma cervix, among others. He is considered a top oncologist in India for these conditions.
Yes, Dr. Madala Ravikrishna is experienced in advanced cancer therapies, including chemotherapy, targeted therapy, and immunotherapy, based on his qualifications and research involvement.
You can schedule a consultation with Dr. Madala Ravikrishna by contacting the Cancer Rounds team, who can assist with appointments and virtual consultations.
Yes, Dr. Madala Ravikrishna has numerous publications and presentations at prestigious conferences like the ASCO Annual Meeting, focusing on areas such as checkpoint inhibitor accessibility and prognostic markers in cancer.
Absolutely, Dr. Madala Ravikrishna is known for his sincere and disciplined patient-centred approach, ensuring personalised care and clear communication for all his patients.
Yes, international patients can seek treatment from Dr. Madala Ravikrishna, with assistance from the Cancer Rounds team for language support, visa, travel, and pre-treatment virtual consultations.
